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Summary 
It has been suggested that epidermal Langerhans cells (LC) bearing immunoglobulin E (IgE) 
may be involved in the genesis of atopic disease. The identity of the IgE receptor(s) on LC remained 
unclear, although it represents a crucial point in understanding cellular events linked to the binding 
of allergens to LC via IgE. In this report, we demonstrate that epidermal LC express the high 
affinity receptor for the Fc fragment of IgE (FceRI) which has, so far, only been described on 
mast cells and basophils.  Epidermal LC react with antibodies specific for the u  subunit of the 
tetrameric (oL,~,23') FceRI. Specific transcripts for Fc~RIo~ and FceRI3~ were detected in LC 
and correspond to  those of human basophils and of the human basophil cell line KU812. 
Furthermore, human basophils, KU812 cells, and LC express the putative B subunit. Thus human 
LC express the complete structure of FceRI. This finding opens new perspectives in the putative 
functional role of this structure on antigen-presenting cells. 
T 
he demonstration of IgE molecules on epidermal Lang- 
erhans cells (LC) 1 in patients with atopic dermatitis has 
implied that these cells should perform a major function in 
the pathophysiology of atopic disease (1, 2). Although ini- 
tially, only receptors for the Fc fragment of IgG were identified 
on epidermal LC (3,  4),  the low affinity  receptor for IgE 
FceRII/CD23 (5) and the human IgE binding protein (eBP) 
(6) have now also been found on these cells in lesional,  as 
well as in normal skin. However, attempts to completely  block 
IgE binding on LC by a variety of anti-FceRII/CD23, anti- 
eBP, and/or anti-Fc3,R reagents remained unsuccessful, sug- 
gesting the presence of a third IgE-binding structure actu- 
ally responsible for a part of the IgE-binding capacity of LC. 
We report here, that normal human LC also express the high 
a~nity receptor for IgE, Fcelkl, demonstrating that the pres- 
ence of this  structure is  not restricted  to  mast cells  and 
basophils. Our results also document the presence of the puta- 
tive/~ chain on both human basophils and LC. 
1 Abbreviations used in this paper: BP, binding protein; ECL, enhanced 
chemiluminescence;  LC, Langerhans  cells. 
Materials and Methods 
Individuals and Biopsy Specimens.  Fresh  human skin specimens 
were obtained during plastic abdominal surgery or reduction mam- 
moplasty. 6-mm punch biopsies were taken from the buttocks of 
healthy volunteers. All samples were immediately processed. 
Basophils and Basophilic Cell Line.  Human basophils were ob- 
tained by standard isolation technique from the peripheral blood 
of healthy volunteers (7). The human basophilic KU812 cell line 
was a kind gift from Dr. Becket (Forschungsinstitut, Borstel, Ger- 
many). These cells, which constitutively express FceRI (8), were 
cultured in RPMI 1640 (Gibco, Berlin, Germany) supplemented 
with 5% FCS (Gibco), antibiotics, and antimycotics (Gibco). 
Reagents.  Unlabeled  mAb IOT6 (IgG1; Immunotech, MarseiUe, 
France), and PE-labeled T6/RD1 (IgG1, Coulter Corp., Krefeld, 
Germany) react with CDla which is, in the skin, exclusively  ex- 
pressed on LC (9). Murine mAb 29C6 and 6F7 (both IgG1) were 
raised from mice immunized with a purified chimeric c~ subunit 
ofFceRI (FceRIo  0 expressed in Chinese hamster ovarian  cells (10). 
FITC-labeled goat  anti-mouse  was obtained from Jackson Im- 
munoResearch Labs, Inc. (West Grove, PA) and unlabeled IgG1 
and PE-labeled IgG1 from Becton Dickinson & Co. (Mountain 
View, CA). For immunohistologic purposes, we also used rabbit 
anti-mouse  Ig  antibody  and  alkaline-phosphatase  mouse 
anti-alkaline-phosphatase complexes (Dakopatts, Hamburg, Ger- 
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Pad Laboratories,  Richmond, CA) was used for immunoblot anal- 
),sis. Oligonucleotides were synthesized by Applig~ne (Illkirch, 
France). 
In Situ Immunolabeling on Cryosections.  6-#m cryosections  were 
prepared from the punch biopsies, air-dried, fixed for 10 min in 
pure acetone, and then processed for immunohistochemistry using 
the mAb IOT6a, 29C6, 6F7, or the IgG1 isotype control (all at 
10  gg/ml)  and  the  alkaline-phosphatase mouse  anti-alkaline- 
phosphatase technique as described previously in detail (2). 
Preparation of Epidermal Cell Suspensions and Enrichment of LC. 
Isolation and enrichment of LC from fresh human skin specimens 
was performed as described in detail elsewhere (5). 
Flow Cytometric Analysis of FceRI Expression on Epidermal Cells. 
10  s  I.C-enriched EC  were incubated  for  30  min  with  heat- 
inactivated AB serum. After several washes in PBS supplemented 
with 1% FCS and 0.1% sodium azide, doublestaining experiments 
were performed by first incubating (1 h, 4~  the cells with either 
29C6 or 6F7 (both at 10 #g/ml). After washing twice in 1% FCS- 
supplemented PBS, the cells were incubated (1 h, 4~  with FITC- 
labeled goat anti-mouse antibody. Then, after washing twice, cells 
were incubated (30 min, 4~  with normal mouse serum (final 
dilution 1:10) to saturate the second step antibody. The cells were 
washed twice and incubated (30 min, 4~  with the PE-labeled 
mAb T6/RD1 (1 #g/ml). Isotype controls were performed with 
unlabeled IgG1 and PE-labeled mouse IgG1. The cells were then 
washed twice in 1% FCS-supplemented  PBS at 4~  and were ana- 
lyzed by flow cytometry using a FACScan  |  (Becton Dickinson & 
Co.). Fluorescence  parameters were collected using a built-in loga- 
rithmic amplifier, and the data of 10,000 cells obtained with Con- 
sort 30 software were analyzed with the Lysis-I  program (Becton 
Dickinson & Co.). 
lmmunomagnetic Depletion~Purification of CDIa §  Cells.  The 
separation of CDla + LC  for  the  preparation  of LC-depleted 
epidermal cells (EC), or for purification of LC was achieved ac- 
cording to the manufacturer's protocol. The purity of the LC prep- 
aration was controlled after each application on the magnet by light 
microscopy, and the procedure was stopped when unbound cells, 
i.e., keratinocytes and other cells, were  completely removed. Addi- 
tion of the beads and depletion procedure were repeated three to 
four times. The LC depletion of EC was controlled by anti-CDla 
staining and flow cytometric analysis. 
Imrnunobiochemical Analysis of FceRI on Epidermal Cells. Puri- 
fied LC or LC-depleted EC were prepared by positive selection as 
described above. The cells were washed, lysed in NP-40 (Sigma 
Chemical Co.)-containing buffer and 14 #g of protein were sepa- 
rated by 12% SDS-PAGE. Then, separated proteins from purified 
LC or from LC-depleted EC were electroblotted onto nitrocellu- 
lose (Hybond C; Amersham Corp., Arlington Heights, IL). The 
strips were blocked with dry milk, and incubated for 1 h with ei- 
ther the anti-FceRI~  29C6 or the isotype control  (both at  10 
/~g/ml). Binding of the primary antibody was revealed  by incuba- 
tion with a peroxidase-conjugated goat anti-mouse Ig antibody 
followed by an enhanced chemiluminescence  (ECL) Western blot 
detection system, according to the manufacturer's protocol (Amer- 
sham Corp.). 
Amplification of mRNA  Transc@ts.  Total  KNA was isolated 
from purified LC, 1.C-depleted  EC, basophils, and KU812 cells by 
standard procedure (11), and eDNA was synthesized by extension 
of  3 pmol of  reverse primers specific  for tryptase,  FceRIo~,  or FceRI3, 
on  100  ng of total  RNA by Moloney routine leukemia virus 
(MoMLV) reverse transcriptase (Gibco). The second-strand synthesis 
and 30 cycles of amplification were performed directly after the 
reverse transcription step by adding 10 pmol of direct primers, 10 
pmol of the reverse primers, 1.25 mM of each dNTP, and 1 U of 
Taq DNA Polymerase  (Perkin-Elmer  Cetus Corp., Norwalk, CT). 
For FceRIfl, eDNA was synthesized by extension of 10 pmol of 
reverse primer on 100 ng of total LC-RNA, or 1/~g of total RNA 
from  basophils. The  second-strand synthesis and  35  cycles of 
amplification were performed by adding 20 pmol of direct primer 
and 50 pmol of the reverse primer, 1.25 mM of each dNTP, and 
1 U ofTaq polymerase. Temperatures  were 94~  for denaturation, 
55~  for annealing of FceRIc~ and FceRI% 58~  for annealing 
of FceRIB, and 72~  for polymerizations. Sequences of PCR 
primers were as follows: for tryptase based on (12): reverse pri- 
mer 5'-GGATCCAGTCCAAGTAGTAG-3',  and direct primer 5'- 
CTCCCTCATCCACCCCCAGT-Y; for FceKIc~  based  on (13): re- 
verse primer 5'-CTTAGGATGTGGGTTCAGAAGT-Y,  and direct 
primer  5'-GACAGTGGAGAATACAAATGTCA-Y;  for  FceRI/~ 
based on (14): reverse primer 5'-TAATTCTTCATAAAGACGAT- 
CATC(A,T,G,orC)GG-3'  and direct primer 5'-ATATGCCTTTGTT- 
TTGGAACAATIGTITG-Y; for FceRI3, based on (15): reverse 
primer  5'-TAGGGCCAGCTGGTGTTAATGGCA-3',  and direct 
primer 5'-GATGATTCCAGCAGTGGTCTTGCT-3'.  PCR prod- 
ucts were then electrophoresed on a 2% agarose gel. 
Cloning and Sequencing of PCR Amplified Products.  After RT- 
PCR, the fragments were digested with 10 U $1 nuclease (Ap- 
plig~ne) for 10 min, at room temperature to increase the efficiency 
of  cloning. Then, they were treated with 5 U Kleenow DNA poly- 
merase (Applig~ne), and the resulting DNA products were cloned 
in the EcoRV restriction site of pKS + (Stratagene Inc., La Jolla, 
CA). Three independent clones were sequenced using Sequenase 
2.0 sequencing kit (US Biochemical, Cleveland, OH) and Hydro- 
link sequencing gel matrix (AT Biochem, Malvern, PA). RT-PCR 
artifacts were excluded by deduction of the nucleotide sequence 
from at least two identical results. 
Southern Blot Analysis.  Alkaline  blotting and Southern hybridi- 
zations were performed on Hybond N +TM membranes (Amersham 
Corp.) according to the manufacturer's conditions. Oligonucleo- 
tide  probes were labeled with  T4  polynucleotide kinase and 
3/-[32p]ATP, and then hybridized to the blot at 50~  Sequences 
of  the probes for Southern  blot are 5'-GAGAGTGAACCTGTGTAC- 
Y, 5'-AGAATCK}TGAGAAACAGC-Y,  5'-AATTGTCCTCACCC- 
TCC-3', and 5'-CCTCCCACCGCCATTTC-Y, specific  for FceRc~, 
FceR~, FceR'y and tryptase respectively. 
Results and Discussion 
Immunodetection of  FceRI on Epidermal LC.  Fc6RI is a tetra- 
meric structure composed of  one 50-55-kD ol chain (FceKIot), 
one 33-kD fl chain (FceRIfl), and two disulphide-linked  iden- 
tical 7-9-kD 3' chains (FceRI'y) (16). Recently, a series of 
anti-FceKIoe mAbs were raised from mice immunized with 
a purified chimeric FceRIol expressed  in Chinese hamster 
ovarian cells (10). Using two of these reagents, the anti-FceRIot 
antibodies 6F7 and 29C6, we investigated the expression  of 
Fc.eRIo~ on cryosections from normal human skin by immuno- 
histochemistry. Positive staining was found not only on dermal 
mast cells but also on some dermal dendritic cells and, most 
important, on dendritic cells in a suprabasal  localization in 
the epidermis (Fig.  1 A) where mast cells have never been 
observed.  Preliminary experiments on cryosections revealed 
that, as expected from the characterization  of these antibodies 
(10), 6F7 blocks the IgE binding on epidermal dendritic cells, 
as well as on dermal mast cells, while 29C6 is ineffective. 
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EC and purified LC were prepared by the means ofimmunomagnetic  sepa- 
ration. Cell lysates from purified I.C (lanes 1 and 3) and LC-depleted EC 
(lanes 2 and 4) were separated by 12% SDS-PAGE, electroblotted  onto 
nitrocellulose, and incubated with either the anti-FceRIc~  mAb 29C6 (lanes 
1 and 2), or the isotype control (lanes 3 and 4). 
Figure 1,  Immunocytochemical staining  of FceRl~ on human LC. (.4) 
Anti-Fc~Pdc~  antibody stains resident human LC. Positive staining is ob- 
served on epidermal dendritic calls (~,-). Positive control is obtained by 
the reactivity of dermal mast cells (4) on the very same sections. (/3) 
Flow cytometric analysis  of the surface expression of the ~ chain of FcERI 
on freshly isolated human LC. Double labeling was performed with the 
PE-labeled  anti-CDla mAb T6/RD1 and the anti-FceRIc~  antibodies 29C6 
(b) or 6F7 (c). Irrelevant mouse IgG1 was used for control purposes (a). 
To ascertain that FceP,.I-reactive epidermal dendritic cells 
were LC, double-labeling experiments and flow cytometric 
analysis were performed on freshly isolated LC-enriched EC 
using anti-FceRIoc and anti-CDla reagents. As expected, anti- 
FceKIo~ antibodies only reacted with CDla-expressing EC, 
i.e., with LC (Fig. 1 B, panels b and c), thus excluding a con- 
tamination of isolated EC with other FceRIol-expressing cells, 
e.g., mast cells. 
Biochemical characterization of the anti-FcdLIce  reactive 
structure by immunoblot analysis on lysates from purified 
LC revealed a structure of an apparent molecular mass of 50 
kD (Fig. 2, lane 1), which is consistent with the oe subunit 
of FcetLI (16). The fact that lysates from LC-depleted EC 
failed to react with anti-FceRIc~ antibodies (Fig.  2, lane 2) 
strongly indicates that, in the epidermal compartment, FceRIcr 
expression is restricted to LC. 
Identification of  the FceRI ol and y Subunits mRNA in LC.  A 
molecular genetic approach based on KT-PCR with specific 
primers for human FceKIoe and FCeKI3, was chosen to fur- 
ther characterize the structure of FceRI on human LC. Agarose 
gel electrophoresis analysis of the amplification products ob- 
tained from purified LC using the primers for FceKI subunits 
revealed the predicted 495- and 364-bp fragments for FceKIcx 
and FceKI% respectively (Fig. 3 b, lanes I and 3). These frag- 
ments correlated exactly with the results obtained with pe- 
ripheral blood basophils (Fig. 3 b, lanes 5 and 7) and KU812 
cells (not shown) which were used as a positive control. The 
specificity of the fragments was confirmed by restriction en- 
zyme analysis of the KT-PCI~ products of purified LC and 
basophils (with HindlI, PvulI, and Sail for the 3, chain, and 
with StuI, PvulI for the cx chain, data not shown), and by 
Southern analysis with oligonucleotidic probes specific for 
Fc~RIc~ (Fig. 3 c, lanes 1 and 5) and FceKI'y (Fig. 3 c, lanes 
3 and 7). KT-PCtL experiments using the primers for Fc~KIc~ 
and FceRI7 on KNA from LC-depleted EC remained nega- 
tive,  while weakly positive in crude EC KNA  (data  not 
shown). It should be mentioned that the possibility of a con- 
tamination by dermal mast cells or basophils was formally 
excluded in either condition, since KT-PCIL experiments using 
1287  Bieber et al. Figure 3.  Analysis of KT-PCK-ampLified transcripts of tryptase (a) and of the or, ~, and 7  subunits of FceRI (b and c) from human purified LC 
(a, lane 4; 6 and c, lanes I-3),  from human basophils (a, lane I; b and c, lanes 5-7),  and the cell Line KU812 (a, lane 3). Purified LC were prepared 
by immunomagnetic  separation, and basophils were obtained  by gradient density centrifugation of peripheral blood. (a and 6) Ethidium  bromide staining 
of the dectrophoretic gds. (c) Autoradiogram  of the Southern blot hybridized  with oligonudeotides specific for the three subunits of FceKL Fceglc~: 
b and c, lanes I and 5.  FceKI~: b and c, lanes 2 and 6. FceRIT: b and c, lanes 3 and 7. Sizes of HaeIII-digested ~  X 174 (1,358, 1,078, 872, 603, 
and 310-bp DNA fragments): a, lane 2, and of Taq 1-digested pBR322 (1,444, 1,305, 475, 368, 315, 313, and 141-bp DNA fragments): b, lane 4. 
L 
H~  1  ata tgc ctt  tgt  ttt  qga  aca  atg gig  tgC  TCT GTA CTT GAT ATT  TCA CAC ATT ~G  ~A  GAC  ATT TTT TCA TCA 
III  II  II  II  III  II  II  II  I  II  I  II  I  I 
209  A~A TGC CTT TGT TTT GGA A~  ATT GTC T~  GTA CTC TAT GTT TCA GAC TTT GAT ~  ~  GTG CTT TTA CTT 
CLCFGTIVC  @~yV~DFDEEVLLL 
~176  h~  F  KA@@@@@@@IF@S  I  @@M@ 
H~  76  TTT ~  GCA  T  TAT CCA TTC  T~  G~  GCC ATA TTT TTT TCT ATT  TCT GGA ATG  TTG  TCA ATT ATA  G~  A~ 
I  I  Ill  I  III  III  III  III  II  II  I  I  III  I  I  XII  III  I  III  III  I~I  II  III  II 
284  TAT ~  CTA ~C  TAT C~  T~  T~  GGT GCA GTG CTG TTT GTT TTG TCT G~  TTT  TTG  ATC  TCC  G~  A~ 
~  ~  ~  |174174174174174174  ~  ~  |  ~  ~  |174  ￿9  |  @|174174 
h,  ~|  ~  ￿9  @|174174  ￿9174  |  A  |174174  G  |174169174 
H~ 151  AGA ~T  GCA ACA TAT CTG GTG A~  CTG G~  ~C  ACT GCC AGC AGC ATA GCT  G  GGA ACG G~  ATT 
I  I  II  II  III  III  III  III  II  III  III  III  III  I  I  ~  I  III  III  II  III  II  III  II  II 
359  ~  ~C  ACA  TTG  TAT CTG G~  A~  ~IA~  CTG ~  ~C  ATT GTC AGT A~  ATC ~T  GCA G~  ACG GGG ATC 
~  |  ￿9  ~@|174  |174  |  ~  ~  ￿9174174174  ~  ￿9174174174 
H~  226  ACC ATC CTG ATC ATC ~C  C~  G  ~G  A~  TTG GCC TAT ATC  C  ATC CAC AGT  TGC  G  TTT TTT GAG ACC 
II  II  III  III  II  II  III  II  I  III  X  I  II  II  I  I  I  I  II  I 
434  GCC ATG CTG ATC  CTC ~T  C~  ACC ~T  ~C  TTC GCT  TAT  ATG  ~C  ~C  T~  ~G  --- ~T  GTA ACC G~  GAC GAC 
.o 
H~  301  ~G  TGC  TTT A~  ~T  TCC  T~  TCC  ACT  ~  ATT  GTA  GTG  ATG ATG  CTG  TTT CTC  ACC  ATT  CTG G~  CTT  GGT AGT 
III  III  III  II  II  II  II  III  I  lII  II  III  III  III  III  III  III  II  III  I  II  X  III 
509  GGC TGC TTT GTG ~T  TC~ T~  ACC A~  GAA CTG  ~GTG TTG ATG ATG CTG TTT CTC ACC ATC CTG GCC TTT T~  AGT 
H~  376  GCT GTG TCA CTC ACA ATC TGT GGA GCT GGG G  G~  CTC ~  GGA  C  ~G  GTT ccc gut  gut  cgt  ctt  tat  gaa  gaa  tta 
III  ~II  I  II  II  III  I  I  I  III  II  I  II  I  III  II 
584  GCT GTG TTG TTC ACT ATC  TAT AGG ATT ~A  C~  GAG TTA G~  AGT ~  ~G  GTC CCA GAT GAT CGT CTT  TAT G~  G~  TTA 
|174174174174174174 
Fibre  4.  Ana~is of the human basophil cDNA ~gment ~plified with mufine ~e~B-d~ved  oligonuc~ti~s.  Nucl~ti~c  s~uence of the 
human cDNA fragment (HB) is compa~ with the murine ~eKI~ cDNA (M~). Conse~  bases a~ linked ~  ~. The numbem in the le~ ma~n 
rear to the nucleotide position within the human cDNA ~agment or the p~Lish~ mufine cDNA sequence (14). Sequences of the primers a~ not~ 
in small lette~.  The deduced amino acid sequence encod~ ~  the human cDNA is ~ven using the single-letter code (h~),  and is compa~ ~th 
the murine ~eKIB amino acid sequence (roB); (c~)  conserved  ~sidues. (Boxes) tmnsmemb~ne domains (14). Note that the intmqto~asm~ domain 
(IISEK ....  YLVRG) is wen conse~ed  in human and mouse. 
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LC RNA (Fig. 3 a, lane 4), while a fragment of ~620 bp 
was easily amplified from peripheral blood basophils RNA 
and from the control cell line KU812 ILNA (Fig. 3 a, lanes 
1 and 3, respectively). Identity of this fragment was checked 
by restriction enzyme analysis (with PvulI and PstI) and by 
Southern analysis (data not shown). Thus LC express at least 
the c~ and 3' chains of FceILl. 
Characterization of a Human ~ Chain cDNA Fragment and 
Detection of the Fc6RIB mRNA Expressed in LC.  Transfec- 
tion experiments have revealed that the IgE binding capacity 
of FceILI is confined to the c~ subunit (18) and that, in humans, 
the cotransfection of FceRI3' appears necessary and sufficient 
for the expression of FceRIc~ at the cell surface (19).  Thus 
the question remained whether human basophils and LC ex- 
press a putative B chain. Since cloning and sequencing of the 
human FceRI/3 have not yet been published, tLT-PCIL of the 
human Fc~R/~ was attempted using oligonucleotides designed 
on the basis of two observations: (a) the murine FceILI~ and 
Ly 44, the routine equivalent of CD20, are structurally ho- 
mologous and include four transmembrane domains; (b) the 
amino acid sequences of the murine Ly 44 and the human 
CD20 are quite well conserved, especially within their trans- 
membrane domains (20). Moreover, given that cysteines should 
be very probably conserved in the transmembrane domains, 
one primer corresponding to nucleotide numbers 209-238 
of the mouse FceRIB cDNA (14) was synthesized, whereas 
the other primer was deduced from the COOH-terminal in- 
tracytoplasmic domain. To increase the probability of success 
of the tLT-PCR, two inosines and one codon degeneracy were 
introduced in the first and second primers, respectively. We 
thereby isolated a 457-bp product from total RNA of pe- 
ripheral basophils (Fig. 3 b, lane 6). Cloning and sequencing 
of this fragment revealed 71% homology to the corresponding 
fragment of the FceRIB in the mouse (Fig.  4).  This frag- 
ment encodes a polypeptide that presents 54% identity with 
a portion of the mouse FceRI~, the most homologous re- 
gion (68% identity) being the transmembrane domains. By 
screening EMBL and SWISS-PILOT databanks using the PC- 
Gene program, significant homologies were found only with 
the mouse and rat FcEILI~. Moreover, the same fragment could 
be amplified by RT-PCIL from KU812 RNA (data not shown). 
Given these data, we assume that we have isolated a cDNA 
fragment of the human B chain. Using these primers, we 
then amplified transcripts from total RNA of purified LC 
and obtained the expected fragment of 457 bp (Fig. 3 b, lane 
2). The identity of this fragment was confirmed by Southern 
analysis (Fig.  3 c, lane 2) using an oligonucleotide deduced 
from the sequence of the above described cDNA cloned from 
the basophils  (Fig.  3 c, lane 6). 
Taken together, our results clearly demonstrate that resi- 
dent or freshly isolated human LC express the three compo- 
nents of FceRI.  To our knowledge, this is the first report 
on the expression of FceRI on cells distinct from mast cells 
and basophils.  It remains to be determined whether, as for 
mast cells or bone marrow-derived precursors of basophils 
(21), cross-linking of IgE via FceP,  I on LC may activate the 
cells or induce the secretion of cytokines, which in turn pos- 
sibly initiate a series of events leading to inflammatory reac- 
tions in the skin or other tissues where these cells are localized. 
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